Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet [Etelcalcetida controla el hiperparatiroidismo secundario y eleva los niveles de esclerostina en pacientes en hemodiálisis previamente no controlados con cinacalcet]

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Pereira, LAL (Author) Other; Meng, C (Author) Other; Amoedo, MAG (Author) Other; Mendes, MTDSCPF (Author) Other; Marques, MAMP (Author) Other; João Frazão (Author) FMUP; Weigert, ALL (Author) Other

Journal

Title: Nefrología (English Edition)

Pages: 197-203

ISSN: 2013-2514

Publisher: Sociedad Española de Nefrología

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 2 Citations

Other information

Authenticus ID: P-00X-K1T

DOI: 10.1016/j.nefroe.2022.11.014

Abstract (EN): Introduction: There is scarce clinical experience with etelcalcetide in patients with secondary hyperparathyroidism uncontrolled with cinacalcet. The effect of etelcalcetide on serum sclerostin levels remains to be clarified. Materials and methods: Prospective cohort study in prevalent hemodialysis patients with uncontrolled sHPT under cinacalcet for at least 3 months, mean parathyroid hormone (PTH) > 800 pg/mL and calcium (Ca) > 8.3 mg/dL. Etelcalcetide 5 mg IV/HD was initiated after cinacalcet washout. Levels of PTH, Ca, and phosphorus (Pi) followed monthly for 6 months. Plasma sclerostin levels measured before etelcalcetide treatment and after 6 months. Results: Thirty-four patients were enrolled, 19 (55.9%) male gender. Mean age 60.7 (± 12.3) years; median time on HD 82.5 (7¿296) months and median cinacalcet dose was 180 mg/week (Interquartile Range: 180¿270). Serum Ca, Pi and PTH levels showed a significant reduction after etelcalcetide treatment from 8.8 mg/dL, 5.4 mg/dL and 1005 pg/mL to 8.1 mg/dL (p = 0.08), 4.9 mg/dL (p = 0.01) and 702 pg/mL (p < 0.001), respectively. Median etelcalcetide dose remained at 5 mg/HD. Plasma sclerostin concentration increased from 35.66 pmol/L (IQR11.94¿54.58) to 71.05 pmol/L (IQR54.43¿84.91) (p < 0.0001). Conclusion: Etelcalcetide improved sHPT control in this group of patients, previously under cinacalcet treatment, and significantly increased plasma sclerostin concentration. The impact of etelcalcetide treatment on sclerostin levels is a novel finding. © 2021 Sociedad Española de Nefrología

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7